Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ).
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced that its investigational new drug application for SKB518, an innovative antibody-drug conjugate for advanced solid tumors, has been cleared by the US FDA for clinical studies. This clearance marks a significant step in the company’s efforts to advance its proprietary ADC technology, showcasing promising preclinical efficacy and safety, and potentially enhancing its position in the biopharmaceutical industry.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development of innovative drugs, particularly in the field of antibody-drug conjugates (ADCs) for treating advanced solid tumors.
YTD Price Performance: 74.77%
Average Trading Volume: 581,243
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$64.86B
Learn more about 6990 stock on TipRanks’ Stock Analysis page.